SenoVax

Company collaborating with FDA to advance senolytic immunotherapy (SenoVax™) into clinical trials for NSCLC MIAMI, Sept. 17, 2025 /PRNewswire/ -- Immorta Bio Inc., a scientific longevity company dedicated to "Treating Diseases of Aging and Treating Aging as Disease™," today announced the appointment of Gilberto de Lima Lopes Jr., MD, MBA, FAMS, to its Strategic Advisory Board. A video of Dr. Lopes discussing Immorta Bio is available here. Continue Reading Immorta Bio, a scientific longevity company, is pleased to welcome Dr. Gilberto Lopes, MD, to its Strategic Advisory Board. Dr. Lopes is globally recognized for leadership in lung cancer and immuno-oncology. He was principal investigator of KEYNOTE-042, the trial that supported the 2019 FDA first-line approval of pembrolizumab (Keytruda®) in PD-L1–positive advanced NSCLC, broadening access to checkpoint inhibition for hundreds of thousands of patients worldwide since approval. "We are honored to welcome a medical pioneer who helped bring game-changing immunotherapy to lung cancer," said Boris N. Reznik, PhD, Chairman and CEO of Immorta Bio. "With Dr. Lopes' guidance, we aim to deliver the next leap— senolytic immunotherapy—to patients who need new options." Immorta Bio's lead program, SenoVax™, is a first-in-class senolytic immunotherapy designed to train the immune system to selectively eliminate senescent cells—aged, dysfunctional cells that accumulate in tumors and their microenvironment, and are associated with immune evasion and resistance to therapy. In preclinical studies, SenoVax™ has demonstrated anti-tumor activity across multiple solid tumor models, including lung, breast, glioma, and pancreatic cancers, and synergy with checkpoint inhibitors. The company is working with the U.S. Food and Drug Administration (FDA) to advance SenoVax™ into a Phase I/IIa study in advanced NSCLC. "Our SenoVax™ program shows that removing senescent cells can de-shield tumors and enable immune-mediated destruction," said Thomas E. Ichim, PhD, President and Chief Scientific Officer of Immorta Bio. "Beyond oncology, targeting senescence has the potential to restore youthful immune and regenerative function, a cornerstone of our longevity vision." "Joining Immorta Bio is an exciting opportunity to extend the promise of immunotherapy beyond traditional cancer care into longevity and healthy aging," said Dr. Gilberto Lopes. "The concept behind SenoVax™— targeting senescent cells to enhance anti-tumor immunity—builds on the foundation established by checkpoint inhibitors like pembrolizumab. I look forward to helping guide the translation of this innovative science to patients." About Immorta Bio Immorta Bio Inc. is a longevity-focused biotechnology company developing personalized cellular and immune therapeutics aimed at " Treating Diseases of Aging and Treating Aging as Disease™." The company's platforms include SenoVax™ (senolytic immunotherapy) and StemCellRevivify™ (personalized cellular rejuvenation and exosomes), with near-term clinical entry in advanced NSCLC. Learn more at immortabio.com. Media & Investor Contact Immorta Bio Inc. Dr. Boris N. Reznik +1 (305) 632-2939 [email protected] Keytruda® is a registered trademark of Merck & Co., Inc. Forward-looking statements apply SOURCE Immorta Bio Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Longevity Company to Present alongside Pfizer and University of Pittsburgh at Clinical Immunology Symposium MIAMI, May 5, 2025 /PRNewswire/ -- Immorta Bio Inc, a scientific longevity company dedicated to "Treating Diseases of Aging and Treating Aging as Disease", announced it is presenting a talk called "Immunologically Mediated Senolysis" at the "Clinical Immunology Symposium" of the American Association of Immunologists Annual Meeting. Immorta Bio's talk will be accompanied by presentations from Pfizer1 and University of Pittsburgh2. The talk will occur Monday, May 5 | 8:15 AM – 10:15 AM | Room 316C at the Haw 'ai Convention Center. Immorta Bio is the first company to develop a "senolytic immunotherapy" for treatment of cancer and aging. This treatment comprises of training the immune system of patients to selectively kill "senescent cells" that promote aging and act as a shield to protect cancer against immune responses. By removing this defense mechanism, cancer becomes susceptible to immune attack. The Company has shown that its lead senolytic immunotherapy product, SenoVax™, is capable of destroying lung, breast, pancreatic and brain cancers, as well as melanoma3 in animal models. "Having been chosen to present our work on using the immune system to fight cancer and aging in such an esteemed panel is truly an honor," said Dr. Thomas Ichim, President and Chief Scientific Officer of Immorta Bio. T cell mediated mechanisms of how SenoVax™ enables its anticancer effects have previously been published in the peer-reviewed literature with collaborators at University of California San Diego, Georgetown University, Ceders Sainai, and Calidi Bio4. Additionally, the Company recently demonstrated that natural killer cell activation as a result of SenoVax™ therapy also plays a role in stimulation of cancer destruction5. "We have founded Immorta Bio on the principle of 'Scientific' Longevity," said Dr. Boris Reznik, President and CEO of Immorta Bio. "There is no better validation of our science than to be chosen to give an oral presentation at such a prestigious and exclusive scientific gathering as AAI2025." About Immorta Bio Immorta Bio Inc., a scientific longevity company focused on "Treating Diseases of Aging and Treating Aging as Disease™," leverages anti-aging technologies to tackle pressing medical challenges, from advanced cancers to other age-related conditions. To learn more about Immorta Bio's research initiatives, visit immortabio.com , LinkedIn and X . Company Contact Dr. Boris Reznik Immorta Bio +1 305-632-2939 @immortabio 1 Eleanore Hendrickson, Pfizer, Myeloid-targeting Immune-Stimulating Antibody-TLR agonist Conjugate (ISAC) for anti-tumor immunity 2 Adam Soloff, Univ. of Pittsburgh, USA, Lung cancer in female never smokers: are pulmonary macrophages to blame? 3 4 5 SOURCE Immorta Bio Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED